Andere Sprachen Vigil Neuroscience, Inc.

Aktien

A3DCFS

US92673K1088

VIGL

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
3.03 ^USD	+10.58%		+11.81%	-10.36%

17.04.	Vigil Neuroscience, Inc. präsentiert die wichtigsten Ergebnisse der Illuminate & Ignite Studien in ALSP auf der Jahrestagung 2024 der American Academy of Neurology	CI
26.03.	VIGIL NEUROSCIENCE, INC. : Wedbush gibt eine Kauf-Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting	17.04.
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting	17.04.
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	26.03.
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.03.
North American Morning Briefing : Markets Steady -2-	26.03.
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer	20.03.
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20.03.
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer	20.03.
Vigil Neuroscience, Inc. Announces Executive Changes	20.03.
North American Morning Briefing : Stock Futures -2-	19.03.
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13.03.
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting	13.03.
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days	12.03.
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024	06.03.
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29.02.
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024	29.02.
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference	07.02.
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones	03.01.
North American Morning Briefing : S&P 500 Futures -2-	20.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vigil Neuroscience, Inc.

Aktien

A3DCFS

US92673K1088

VIGL

Andere Sprachen

Filter